Book a Meeting

Anti-Lectin-like transcript 1 Antibody, Non-Fucosylated (BioBet-723ZP) (CAT#: BioBet-723ZP) Datasheet

Target
Lectin-like transcript 1
Isotype
IgG
Description
ADCC-Enhanced anti-Lectin-like transcript 1 (LLT12F1A5) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Autoimmune Diseases
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Lectin-like transcript 1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CLEC2D
Full Name
C-type lectin domain family 2, member D
Background
This gene encodes a member of the natural killer cell receptor C-type lectin family. The encoded protein inhibits osteoclast formation and contains a transmembrane domain near the N-terminus as well as the C-type lectin-like extracellular domain. Several alternatively spliced transcript variants have been identified for this gene.
Alternative Names
CLEC2D; C-type lectin domain family 2, member D; CLAX; LLT1; OCIL; C-type lectin domain family 2 member D; LLT-1; C-type lectin related f; lectin-like transcript 1; lectin-like NK cell receptor; osteoclast inhibitory lectin; C-type lectin superfamily 2, member D
Gene ID
29121
UniProt ID
P19022
Cellular Localization
Plasma membrane
Related Pathways
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Function
The KLRB1 receptor protects target cells from natural killer cell-mediated lysis. Inhibit osteoclast formation and inhibit bone resorption. Regulate the release of interferon. Combines high molecular weight sulfated glycosaminoglycans.
Post-translational modifications
1.N-glycosylated 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn95 and Asn147
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
LLT12F1A5
Host
Chimeric
Species Reactivity
Human
Description
This is a monoclonal antibody that is capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibody and to cells that express such antibody. antibody have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
Antibody Indication
Autoimmune Diseases

Autoimmune Diseases

Related Products

Anti-Lectin-like transcript 1 Antibody, Non-Fucosylated (BioBet-722ZP) (CAT#: BioBet-722ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.